Dear Editor,

COVID-19, a novel coronavirus, has spread throughout the world. Because of exponential growth, social distancing is a critical strategy to decrease transmission. Thus, educational medical communities from many countries have transitioned to online didactics.1 Recommendations to cancel all non-urgent visits have been proposed.2 Our dermatology department has cancelled all elective outpatient visits and surgeries. Consequently, trainees’ surgical skills have been severely affected. To continue our educational programme, we have implemented measures to help our trainees continue learning and maintaining surgical skills.

We continued our educational programme with a general review of basic and advanced dermatologic surgery using PowerPoint presentations using a web-based video conferencing tool. Professors share their knowledge and experiences with trainees and answer any questions. Afterwards, professors apply a hypothetical case scenario so the surgical trainee can decide the surgical approach [Mohs micrographic surgery (MMS) or conventional wide-margin excision (WME)] using a simulator bust model (Diaphanous Zsa Zsa, DermSurg Scientific, Dayton, OH, USA).

Residents design multiple flaps and practise surgical skills in a life-like scenario (Fig. 1) and place the simulator akin to how patients are normally positioned for surgery. Then, with a non-permanent marker they draw a hypothetical skin defect. Depending on the size and location of the cancer, they design and discuss different possible reconstruction flaps. Multiple flap designs are then drawn by the trainees to see which is best suited. To reassure complete comprehension, trainees explain the concepts behind each flap and are assessed by their professors. Drawings from conventional surgical models are easily erased from the bust models with isopropyl alcohol allowing a quick turnaround time for the next case.

The combined use of simulation-based education and digital technologies for dermatologic surgery has been previously reported.3,4 Nicholas et al.5 carried out a pilot study and reported that learners were receptive to the use of simulators in their dermatologic training after a 2-day surgical symposium. More than 90% of the participants agreed that simulators were helpful. Additionally, more than 75% of the participants agreed that simulators were useful in acquiring, refining, assessing and learning these skills. Notably, 90.9% of the participants thought that training using simulators should be mandatory in their residency programme.

It is important to clarify that this educational experience is new for everyone, and we acknowledge that any recommendations we propose are likely to shift in the coming weeks as the advancement of online medical education evolves. Despite the need to polish and improve the dermatological surgery programme with simulators in our department, our experience indicates that surgical trainees learn to train their minds to consider the different flaps and possible reconstructions with 1-hour weekly practices. Our main goal is that when the COVID-19 contingency ends, our trainees will have the confidence and mental ability to treat patients. We want to emphasize that learning and/or practicing with simulators will never substitute a mental ability to treat patients. We want to emphasize that learning and/or practicing with simulators will never substitute a mental ability to treat patients.
advance medical education. The combined use of web-based video conferencing tools and simulators for dermatologic surgery education opens an opportunity for curricular innovations and transformation of medical trainee programmes.

**Funding source**
This article has no funding source.

**References**
1. Rose S. Medical student education in the time of COVID-19. *JAMA* 2020. https://doi.org/10.1001/jama.2020.5227
2. Kwatra SG, Sweren RJ, Grossberg AL. Dermatology practices as vectors for COVID-19 transmission: a call for immediate cessation of non-emergent dermatology visits. *J Am Acad Dermatol* 2020; 82: e179–e180.
Urticarial eruption in coronavirus disease 2019 infection: a case report in Tangerang, Indonesia

Dear Editor,

We have read with great interest the articles regarding cutaneous manifestations in coronavirus disease 2019 (COVID-19) infection. Studies showed 20.4% of COVID-19-infected patients developed cutaneous manifestations and might be the only presenting symptom.1 To date, previous cases reported urticaria as one of the cutaneous manifestations in COVID-19.1–4 This atypical symptom might lead to misdiagnosis, delayed diagnosis and virus transmission, especially in countries where cutaneous manifestation of COVID-19 has not been reported widely such as in Indonesia. We would like to report a case of urticaria in COVID-19-positive non-ICU hospitalized patient from Indonesia to bring awareness to its cutaneous manifestations.

A 51-years-old patient was admitted to our hospital on 12 April 2020 with presenting symptoms including fever, cough, dyspnoea and diarrhoea. His RT-PCR for COVID was positive on 10 April 2020; therefore, he was diagnosed with COVID-19. The patient has history of hypertension, diabetes, dyslipidemia and hyperuricemia on therapy. The vital signs were as follows: blood pressure 160/100 mmHg, pulse rate 106/min, respiratory rate 24/min, temperature 37.1°C and SpO2 97% on room air. The result of the examinations on admission is as follows: low haemoglobin (12.8 g/dL), red blood cell count (4.31 × 106/μL), pO2 (75 mmHg), HCO3 (19.8 mmol/L), total CO2 (20.8 mmol/L), base excess (−5 mmol/L) and high ESR (17 mm/h), LDH (300 U/L), CRP (6.9 mg/dL). Chest CT scan on April 12 showed fibrotic bands in both lungs with no ground-glass opacity. Chest X-ray on April 12 showed bilateral lung opacities predominantly in peripheral, lower zone (Fig. 1). The patient was treated with azithromycin, hydroxychloroquine, cefoperazone-sulbactam, omeprazole and medicines for his comorbidities. On day 3 of hospitalization, suddenly, he developed pruritic urticaria involving the face (Fig. 2a,b) and without involvement of the rest of the skin. It appeared 5 days after the onset of symptoms. However, no urticaria triggers other than viral infection were found, as there was no history of food allergy, drug allergy, chronic urticaria, nor other allergies. There was no history of consuming new medicine in 15 days prior besides COVID-19 treatment in hospital. Oral antihistamine loratadine was added to his treatment with improvement of symptom on the next day. The suspicion of urticaria caused by the medicines given in hospital could be eliminated by the fact his urticaria improved even the medicines continued to be given.

This report was consistent with previous studies, and treatment with oral antihistamines led to clinical improvement as well. A case in Spain reported urticaria in COVID-19-infected patient which biopsy revealed a perivascular infiltrate of lymphocytes, some eosinophils and upper dermal oedema.4 However, biopsy was not done in this case because of the equipment limitation. The authors postulated the pathophysiology of urticaria in COVID-19 might be described by three hypotheses. Firstly, it has widely known that viral infection causes nonimmunological urticaria by mast cell activation through complement activation.5 Secondly, vasculitis might be the underlying cause as in pathophysiology in urticarial vasculitis. Angiotensin-converting enzyme 2 (ACE2), the protein which SARS-CoV-2 uses to enter cells, was widely distributed in human’s body, particularly vascular endothelial. This might lead to formation of antibody-antigen complex, which deposited at vascular wall, which is followed by complement activation and mast cell degranulation.6,7 Thirdly, the urticaria might be associated with bradykinin in Kinin–kallikrein system in conjunction with ACE2. But more studies regarding BK-mediated urticaria are needed.8–10

Figure 1 Chest X-ray on April 21.